Medically reviewed by Paria Sanaty Zadeh, PharmD As you age, your cells naturally wear down, which affects how you look and ...

I have a beloved nephew, but being near him makes me sneeze, wheeze and itch. Ringo, aged four, is a dopey and affectionate ...

Teva Pharmaceuticals and Alvotech have announced that the US Food and Drug Administration (FDA) has approved the Selarsdi ...

Here's everything medical experts want you to know about how vaccines work. Vaccines work by imitating an infection to teach the body how to recognize and defend itself from disease without ...

Kiniksa Pharmaceuticals surpasses Q1 expectations, raises ARCALYST sales guidance. Click here to read an analysis of KNSA ...

For women with mixed urinary incontinence (MUI) who have not had success with conservative treatments, intradetrusor ...

FDA approves Teva and Alvotech's Selarsdi as an interchangeable biosimilar to Stelara, supporting the treatment of multiple ...

The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) ...

The subcutaneous formulation of daratumumab makes treatment a faster and more tolerable process for patients with multiple ...

Using the latest data and perspectives, an international expert panel releases updated recommendations for optimal insulin ...

No more IV drips, cancer patients on immunotherapy can now take the drug in a single injection. The National Health Service ...

This innovative rollout makes England the first country in Europe to adopt the approach at scale. NHS officials expect the treatment to be made available to around 1,200 eligible patients per month.